Infinite Epigenetics, the parent company of TruDiagnostic, has acquired Tally Health, the consumer longevity company co-founded by Harvard geneticist Dr. David Sinclair, in what the company says is the largest acquisition in epigenetic age testing to date.
The deal creates a vertically integrated platform spanning advanced epigenetic diagnostics, the world’s largest private adult DNA methylation datasets, and personalized interventions including longevity-focused supplements. Tally Health will continue as a standalone consumer brand under CEO Melanie Goldey, while Dr. Matthew Dawson continues as CEO of Infinite Epigenetics and TruDiagnostic.
“We believe epigenetics will underpin the next generation of medical diagnostics, shifting healthcare from reactive treatment to proactive, data-driven prevention,” said Dawson. “By combining our scientific infrastructure, proprietary data, and clinical capabilities with Tally Health’s consumer reach, we can accelerate the adoption of epigenetics across healthcare – from research and clinical settings to population-scale applications.”
Infinite Epigenetics operates a CLIA-certified laboratory with 115+ research partnerships with institutions including Harvard, Yale, Duke, and Stanford. Its TruAge and TruHealth testing platforms provide biological age and systems-level health insights. Tally Health brings a consumer platform anchored by the TallyAge Test – an at-home cheek swab epigenetic age test – alongside supplements and personalized recommendations. Tally Health was seeded by L Catterton.
“From day one, Tally Health was built to take the most advanced science of aging and make it actionable for everyday people,” said Goldey. “Joining Infinite Epigenetics allows us to dramatically accelerate that mission by combining best-in-class data, scientific rigor, and consumer experience to deliver a truly end-to-end longevity platform.”
The deal reflects the broader convergence of longevity science with consumer health – a trend increasingly relevant to women’s health as companies across the sector expand from single-condition platforms into healthspan and aging.
